A unique meeting which aims to bring together scientists from academia, the pharmaceutical / biotech sector and antibody suppliers in order to discuss best practices in research antibody validation and help improve antibody validation for the life science community.
The meeting is being organised by the University of Bath as part of it’s 50th anniversary celebrations, and supported by AstraZeneca and CiteAb.
The meeting offers a great chance to hear the latest in antibody validation, interact with leaders in the antibody validation field and contribute to this initiative aimed at helping improve research antibody validation.
More information to come.
Professor Alison’s Haemato-oncology group are particularly experienced in monoclonal antibody production and characterisation and are actively involved in the European Monoclonal Antibodies Network.
The Swedish Human Protein Atlas project, has been set up to allow for a systematic exploration of the human proteome using antibody-based proteomics. Dr Björk is the lab manager of the Cell Profiling group at the SciLifeLab site, Stockholm.
Karine Enesa is a senior scientist in the Affinity Reagent Team at AstraZeneca. Joining the group in 2015, Karine’s main role is to design and validate newly generated mono and polyclonal antibodies. She also optimises antibody based cellular assays.
Arthur Lewis is the Senior R&D Manager of the Pathology team at MedImmune Cambridge. Arthur's current focus is in helping drive new target identification, validation utilising IHC and other tissue based tools as well as developing these into translational clinical studies.
Jason Li, founded Proteintech Group with fellow scientists in 2002. Their goal: provide researchers a reliable, reproducible antibody for every human protein. Proteintech manufactures all antibodies in-house, with an emphasis on developing antibodies from whole proteins.
Deepa Shankar is the Director of R&D at Thermo Fisher Scientific.
Responsible for managing the global output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically the New Product Development (PDM) and Core Product reagents pipelines.
Dr Mike Taussig is founder and CEO of Cambridge Protein Arrays Ltd. and Head of the Protein Technology Group at the Babraham Institute, Cambridge.
The founder or NeuroMab, Dr. Trimmer also has research interests in brain function as it relates to electrical signaling in neurons. Research in his lab is focused on ion channels and their regulation by neuromodulation, and during incidents of epilepsy and ischemia.
More information to come.
Would you like to speak or present a poster at the 2nd International Antibody Validation Meeting?
If you would like to be considered as a speaker or to present a poster at this year's meeting please apply below. Applications welcome from researchers in academia, pharma/biotech and antibody suppliers.Apply now
We hope to see you there! If you have any questions relating to the event, please drop us an email.